{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:25:13Z","timestamp":1761942313207,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.bone.2006.01.163","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T13:21:51Z","timestamp":1146662511000},"page":"369-376","source":"Crossref","is-referenced-by-count":25,"title":["Elevated serum FGF23 concentrations in plasma cell dyscrasias"],"prefix":"10.1016","volume":"39","author":[{"given":"Inge","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Mirams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca S.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2006.01.163_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23","volume":"26","author":"The ADHR consortium","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2006.01.163_bib2","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumour-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2006.01.163_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1210\/jc.86.2.497","article-title":"The autosomal dominant hypophosphataemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumours that cause phosphate wasting","volume":"86","author":"White","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.01.163_bib4","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphataemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J. Clin Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.01.163_bib5","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphataemia","volume":"348","author":"Johnsson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.163_bib6","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","article-title":"Serum FGF23 in normal and disordered phosphorus homeostasis","volume":"18","author":"Weber","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2006.01.163_bib7","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1210\/jc.2002-021919","article-title":"Clinical case seminar. Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia","volume":"88","author":"Nelson","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.01.163_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bone.2003.12.025","article-title":"Resolution of severe, adolescent-onset hypophosphataemic rickets following resection of an FGF23-producing tumour of the distal ulna","volume":"34","author":"Ward","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.01.163_bib9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1074\/jbc.M207872200","article-title":"Human fibroblast growth factor-23 mutant suppress Na+-dependent phosphate co-transport activity and 1\u03b1,25-dihydroxyvitamin D3 production","volume":"278","author":"Saito","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2006.01.163_bib10","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1074\/jbc.M210490200","article-title":"The autosomal dominant hypophosphataemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency","volume":"278","author":"Bai","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2006.01.163_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphataemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2006.01.163_bib12","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1210\/en.2004-0233","article-title":"Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders","volume":"145","author":"Bai","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2006.01.163_bib13","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","article-title":"Transgenic mice expressing fibroblast growth factor 23 under the control of the \u03b11(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis","volume":"145","author":"Larsson","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2006.01.163_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"Robey, FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J. Clin Invest."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2006.01.163_bib15","article-title":"The neutralization of FGF-23 ameliorates hypophosphataemia and rickets in Hyp mice","volume":"18","author":"Aono","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.163_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","article-title":"Homozygous ablation of fibroblast growth factor-23 results in hyperphosphataemia and impaired skeletogenesis, and reverses hypophosphataemia in Phex-deficient mice","volume":"23","author":"Sitara","year":"2004","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bone.2006.01.163_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2006.01.163_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/hmg\/ddi034","article-title":"An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphataemia","volume":"14","author":"Benet-Pages","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bone.2006.01.163_bib19","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1210\/jc.2004-2238","article-title":"A novel recessive mutation in fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis","volume":"90","author":"Larsson","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.01.163_bib20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","article-title":"Bone as a source of FGF23: regulation by phosphate?","volume":"35","author":"Mirams","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.01.163_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bone.2005.03.002","article-title":"Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations","volume":"36","author":"Yu","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.01.163_bib22","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.bone.2006.01.163_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00402-004-0715-0","article-title":"A case of familial tumoral calcinosis in a neonate and review of the literature","volume":"124","author":"Polykandriotis","year":"2004","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"10.1016\/j.bone.2006.01.163_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cytogfr.2005.01.002","article-title":"FGF23 and disorders of phosphate homeostasis","volume":"16","author":"Yu","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bone.2006.01.163_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00355.x","article-title":"The phosphatonin pathway: new insights in phosphate homeostasis","volume":"65","author":"Schiavi","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2006.01.163_bib26","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00016.2003","article-title":"FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization","volume":"285","author":"Quarles","year":"2003","journal-title":"Am. J. Physiol.: Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.01.163_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumours are a single histopathological entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"1","author":"Folpe","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bone.2006.01.163_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0002-9343(87)90081-7","article-title":"Hypophosphataemic osteomalacia and adult Fanconi syndrome due to light-chain nephropathy: another form of oncogenous osteomalacia","volume":"82","author":"Rao","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2006.01.163_bib29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0889-8588(05)70128-3","article-title":"Prognostic factors in multiple myeloma","volume":"13","author":"Rajkumar","year":"1999","journal-title":"Hematol.\/Oncol. Clin. North Am."},{"key":"10.1016\/j.bone.2006.01.163_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2006.01.163_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2006.01.163_bib32","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bone.2006.01.163_bib33","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood.V97.8.2413","article-title":"The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in haematopoietic cells","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2006.01.163_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2004.04814.x","article-title":"Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma","volume":"124","author":"Paterson","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2006.01.163_bib35","first-page":"800","article-title":"Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood","volume":"85","author":"Di Raimondo","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2006.01.163_bib36","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2002-09-2907","article-title":"Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma","volume":"101","author":"Bisping","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bone.2006.01.163_bib37","first-page":"728","article-title":"Expression of vascular endothelial growth factor and its receptors in haematopoietic malignancies","volume":"59","author":"Bellamy","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2006.01.163_bib38","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064","article-title":"Bone marrow neovascularisation, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma","volume":"93","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bone.2006.01.163_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-002-0558-0","article-title":"Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma","volume":"82","author":"Alexandris","year":"2003","journal-title":"Ann. Haematol."},{"key":"10.1016\/j.bone.2006.01.163_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1034\/j.1600-0609.2001.00348.x","article-title":"Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma","volume":"66","author":"Sezer","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2006.01.163_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1349-7006.2002.tb01278.x","article-title":"Elevated levels of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity","volume":"93","author":"Sato","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.bone.2006.01.163_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0093-7754(01)90022-3","article-title":"Bone marrow angiogenesis in patients with active multiple myeloma","volume":"28","author":"Vacca","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bone.2006.01.163_bib43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4065\/80.6.745","article-title":"Elevated fibroblast growth factor 23 in women with malignant ovarian tumours","volume":"80","author":"Tebben","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2006.01.163_bib44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4065\/78.7.826","article-title":"Fibroblast growth factor 23 concentrations in humoral hypercalcaemia of malignancy and hyperparathyroidism","volume":"78","author":"Singh","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2006.01.163_bib45","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM198012113032401","article-title":"Biochemical evaluation of patients with cancer-associated hypercalcaemia: evidence for humoral and nonhumoral groups","volume":"303","author":"Stewart","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.163_bib46","doi-asserted-by":"crossref","first-page":"28265","DOI":"10.1074\/jbc.M202527200","article-title":"Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway","volume":"277","author":"Yamashita","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2006.01.163_bib47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1006\/bbrc.2001.5084","article-title":"FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate","volume":"284","author":"Bowe","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bone.2006.01.163_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bone.2003.10.005","article-title":"MEPE has the properties of an osteoblastic phosphatonin and minhibin","volume":"34","author":"Rowe","year":"2004","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2006.01.163_bib49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI18563","article-title":"Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent","volume":"112","author":"Berndt","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bone.2006.01.163_bib50","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/jc.2004-0357","article-title":"Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors","volume":"90","author":"Carpenter","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.01.163_bib51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0272-6386(97)90207-9","article-title":"Profound hypophosphataemia and isolated hyperphosphaturia in two cases of multiple myeloma","volume":"29","author":"Dash","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bone.2006.01.163_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/014107689308601117","article-title":"Hypophosphataemic osteomalacia due to urinary kappa light chain","volume":"86","author":"Pope","year":"1993","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.bone.2006.01.163_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.163_bib54","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.163_bib55","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.163_bib56","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J. Biol. Chem."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206002493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206002493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:03:44Z","timestamp":1683450224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328206002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S8756328206002493"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2006.01.163","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}